Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Colchicine reduces ischaemic event risk in MI patients

Roshini Claire Anthony
26 Nov 2019
Professor Jean-Claude Tardif

The anti-inflammatory drug colchicine at a dose of 0.5 mg/day significantly reduced the risk of ischaemic cardiovascular (CV) events in individuals with a recent myocardial infarction (MI), according to results of the COLCOT* trial presented at AHA 2019.

“Colchicine, at a low dosage of 0.5 mg/day, significantly reduced the risk of first and total ischaemic CV events by 23 percent and 34 percent, respectively, compared to placebo in patients with a recent MI,” said study author Professor Jean-Claude Tardif from the Montreal Heart Institute in Montreal, Canada.

Study participants were 4,745 individuals (mean age 60.6 years, 19.2 percent female, 20.2 percent with diabetes) with a recent MI (30 days; mean 13.5 days post-MI) who had been treated as per national guidelines (eg, statins plus antiplatelet agents with or without beta-blockers or renin-angiotensin-aldosterone system inhibitors, and undergone percutaneous coronary intervention if planned). They were randomized to receive colchicine (0.5 mg/day; n=2,366) or placebo (n=2,379).

After a median 22.6-month follow-up, colchicine significantly reduced the risk of the primary outcome of CV death, resuscitated cardiac arrest, MI, stroke, and urgent hospitalization for angina requiring revascularization compared with placebo in the intention-to-treat (5.5 percent vs 7.1 percent; hazard ratio [HR], 0.77, 95 percent confidence interval [CI], 0.61–0.96; p=0.02) and per-protocol populations (5.1 percent vs 7.1 percent; HR, 0.71, 95 percent CI, 0.56–0.90; p=0.004). [AHA 2019, LBS1; N Engl J Med 2019;doi;10.1056/NEJMoa1912388]

The impact of colchicine was evident for all components of the primary outcome (CV death: HR, 0.84; resuscitated cardiac arrest: HR, 0.83; MI: HR, 0.91; stroke: HR, 0.26; urgent hospitalization for angina leading to coronary revascularization: HR, 0.50).

“[However, the main results were] due predominantly to a lower incidence of strokes and urgent hospitalizations for angina leading to coronary revascularization,” said the authors.

The secondary composite endpoint comprising CV death, resuscitated cardiac arrest, MI, or stroke was also reduced in the colchicine vs placebo arm (4.7 percent vs 5.5 percent; HR, 0.85, 95 percent CI, 0.66–1.10). There was no significant between-group difference pertaining to overall death, atrial fibrillation, or deep vein thrombosis or pulmonary embolism.

A total of 154 and 223 primary endpoint events (first and recurrent) occurred in colchicine and placebo recipients, respectively, over the follow-up period, at a rate of 0.29 and 0.42 events per 100 patient-months, respectively (rate ratio, 0.66).

Adverse events (AEs) occurred at a comparable rate between colchicine and placebo recipients (16.0 percent vs 15.8 percent) and were primarily gastrointestinal (17.5 percent vs 17.6 percent). Nausea and flatulence were more common in colchicine than placebo recipients (1.8 percent vs 1.0 percent and 0.6 percent vs 0.2 percent; p=0.02 for both). Serious AE incidence was also comparable between groups (16.4 percent vs 17.2 percent), though colchicine recipients had a higher incidence of pneumonia (0.9 percent vs 0.4 percent; p=0.03).

The findings pertain only to patients with a recent MI and as such, more research is required to identify if the benefits of colchicine extend to other high-risk groups, noted Tardif. The upcoming COLCOT-T2D study aims to assess the effect of colchicine on the same outcomes as in COLCOT but in T2D patients without coronary disease, he added. Longer-term follow-up is also needed to establish the benefits and risks of colchicine over a longer period.

“These landmark results provide confirmation that inflammation management reduces CV risk [and demonstrates] successful repurposing of a broadly available and relatively safe generic drug for a new application,” said discussant Assistant Professor Aruna Pradhan from the Brigham and Women’s Hospital in Boston, Massachusetts, US.

The mechanisms behind these benefits still need identifying, added Pradhan. As colchicine is cleared renally, caution is necessary when using this drug in patients with renal impairment, though it is hoped that future trials will help establish the safety of colchicine in these patients.

Assistant Professor Aruna Pradhan

Assistant Professor Aruna Pradhan

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]